Kornimate/medical-research-clean huggingface dataset:
evaluation of advanced practice nurse's management of patients with chronic myeloid leukemia

Conditions: Chronic Myelogenous Leukemia - Chronic Phase

Summary: chronic myeloid leukemia (cml) affects 820 people per year in france (2018), half of them are older than 60 years old. tyrosine kinase inhibitors (tki) are new kind of targeted therapy whose efficiency allow for a high rate of complete molecular response, leading to a disruption of treatment under certain conditions. optimizing cml treatment is a major concern, particularly for adverse events management, treatment compliance and therapeutic response. multiple studies demonstrated that grade ≤ ii adverse events are most likely to be under reported by patients and clinicians. although these adverse events are mostly reported by clinical examination, needing minimal treatment. these toxicities could alter daily and domestic living activities, potentially impacting treatment compliance and therapeutic response. therefore, early detection of these adverse events is a major challenge for the prognosis and care of cml. the advanced practice nurse (apn), a new health care professional, acquired the skills needed to independently follow, manage and care the patients with medical approvals. at international level, many studies, in oncology and in others domains, have been done to demonstrate the added value of the apn, particularly in improving patient's quality of life, management, care of drug-induced adverse events and treatment compliance. in france, because of the recentness of the profession, only few studies were have been conducted. the goal of this study is to demonstrate the benefit of apn in clinical follow-up, quality of life, treatment compliance, and therapeutic response of cml patients. these effects could be managed thanks to early detection and management of ≤ grade ii adverse events during consultation, in partnership with the patients, and in collaborative working.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old. * cml patient in chronic phase, eligible for oral therapy. * newly diagnosed cml and/or initiating oral therapy : * patient changing treatment for non-response or loss of therapeutic response or toxicities, on the condition that these toxicities are resolved or grade i maximum at the time of inclusion. * newly start of oral therapy. * patient eligible to a follow-up by an advanced practice nurse. * patient capable to understand french and complete a questionnaire. exclusion criteria: * patient that had a follow-up \> 3 months by an advanced practice nurse for cml before inclusion. * patient changing treatment for toxicities, if these toxicities are still \> grade i at inclusion. * patient enrolled in another interventional research protocol for cml. * pregnant women. * patient under legal protection, deprived of liberty or unable to be included in a research protocol.

Keywords: advanced practice nursing quality of life adverse event
early detection of cardiac toxicity of trastuzumab (herceptin ®) in patients treated for breast carcinoma: value of magnetic resonance imaging

Conditions: Cancer, Breast; LV Dysfunction

Summary: the main objective of this study is to compare the proportions of late enhancement in patients with left ventricular (lv) dysfunction as herceptin ® and in a control group consisting of patients who did not have lv dysfunction after 6 months under the same treatment.


Eligibility criteria:
inclusion criteria: * women over 18 years * free and informed consent signed * histologically confirmed adenocarcinoma of the breast, metastatic or non-metastatic * lvef\> 50% angioscintigraphy before the start of treatment with herceptin ®, * overexpression of her2 in the invasive component of the primary tumor (3 + 2 + according to ich or with confirmation of positivity by fish or cish) * patient receiving treatment with herceptin ®, * inclusion in the control group: patients treated with herceptin ® episode without lv dysfunction, * for the inclusion in the group lv dysfunction: the appearance of a decrease in lvef during treatment with herceptin ®, angioscintigraphy identified. exclusion criteria: * heart disease or serious medical conditions do not allow to administer herceptin ® (documented history of heart failure, angina requiring treatment, severe dyspnoea at rest or oxygen dependency), * history of ischemic heart disease or myocarditis * known allergy to trastuzumab, murine proteins or any of the excipients * patients with an indication against the mri (claustrophobia, ferromagnetic foreign body, pacemaker or implantable defibrillator, known allergy to gadolinium salts) * renal impairment (creatinine clearance \<60 ml / min according to the mdrd formula) * arrhythmia atrial fibrillation, * contraindications to the administration of dotarem ®, * patient unable to give informed consent, * adult trust, * pregnant or lactating * patient unable to undergo a medical for geographical, social or psychological.

Keywords: cardiac mri cancer breast herceptin lv dysfunction
biological sample collection for research and biobanking

Conditions: Parkinson Disease; Diabetes Mellitus, Type 1; Macular Degeneration; ALS; Cancer; Alzheimer Disease; Huntington Disease

Summary: the new york stem cell foundation (nyscf) research institute is performing this research to study different conditions and diseases by using cells from the body (such as skin or blood cells). nyscf uses these samples to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store these samples for future use. through this research, scientists hope to identify future treatments or even cures.

researchers at nyscf study diverse diseases, conditions, and traits by creating "pluripotent" stem cells. these stem cells can become any cell in the human body, including cells that may be difficult, invasive, or even impossible to obtain directly. for example, researchers may create pancreatic insulin-producing cells to learn more about type 1 diabetes, or brain cells to learn more about parkinson's disease. additionally, researchers perform genetic testing to learn more about dna, a material in most cells that contains instructions for the body's development and functions (such as traits like eye color and risk of certain diseases). a piece of dna that determines the specific role of a cell is called a "gene." if the instructions in a gene are abnormal, this can lead to disease. participation in the study involves: (1) completion of a health questionnaire, (2) providing a skin and/or blood sample from which stem cells may be created, (3) possible collection of a saliva sample for genetic analysis, and (4) possible future follow-up to provide additional information or learn about other research studies. this study is not a clinical trial.

Eligibility criteria:
inclusion criteria: age * 18 years or older or * minor with parent/guardian consent biological sample collection * able and willing to provide: * new samples of blood, skin, and/or saliva specifically for use in this study and/or * excess/leftover samples, cell lines, and/or derivatives that were (or will be) collected for reasons other than this study exclusion criteria: * non-english speaking * wards of the state * for skin samples collected specifically for this study: history of keloid formation, bleeding disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection. * for blood samples collected specifically for this study: bleeding disorder, or other medical condition, if the subject's condition increases the risks associated with blood collection. * for saliva samples: inability to produce sufficient saliva or has a condition that precludes sample collection (such as severe trismus). * for prospective samples: refuse to adhere to nyscf's and/or collaborating site's covid-19 safety protocols during the covid-19 pandemic.

Keywords: stem cell observational biobank disease modeling genetics
retinal oxygen saturation in patients with graves' ophthalmopathy and in normal people

Conditions: Graves' Ophthalmopathy

Summary: find if the retinal function is affected in both the nonsevere and the severe stage of graves' ophthalmopathy (go) by comparing the retinal oxygen saturation of go patients with that of normal people.

graves'ophthalmopathy (go), also called thyroid-associated ophthalmopathy, is often mild and self-limiting, and probably declining in frequency, with only 3-5% of cases posing a threat to eyesight, remaining a pathogenetic enigma and a therapeutic dilemma. in its nonsevere expression, the symptoms and signs include photophobia, foreign body sensation, eyelid retraction, increased intraocular pressure, lagophthalmos, and mild diplopia. in its severe expression, it is a disfiguring and invalidating disease with the optic nerve damaged. however, in this study, we want to find if the retinal vessels is affected in the early stage of the disease through observing the oxygen saturation of the retinal vessels and compare it with that of the normal people.

Eligibility criteria:
inclusion criteria for go patients: 1. conforms to the diagnosis of graves' ophthalmopathy; 2. age \> 18; 3. volunteered to participate in this research, and sign the informed consent. inclusion criteria for control group: 1. age \> 18; 2. diopter within + / - 3d; 3. volunteered to participate in this research, and sign the informed consent. exclusion criteria for go patients: 1. fundus could not be seen clearly; 2. pregnant and lactating women; 3. could not tolerate the examination. exclusion criteria for control group: 1. with severe systemic disease and cause eye lesions; 2. have history of eye disease, ocular trauma and eye surgery impacting on visual function; 3. pregnant and lactating women; 4. could not tolerate the examination.

Keywords: oxygen saturation retinal vessels thyroid associated ophthalmopathy
pth and calcium responses to exercise in older adults experiment 2 (pace sr. 2)

Conditions: Osteoporosis

Summary: declines in serum calcium during exercise may cause increases in markers of bone resorption. this study will determine if preventing the decline serum ionized calcium experienced at the onset of exercise through the use of a "calcium clamp" also prevents increases in blood biomarkers associated with bone resorption.

participants will undergo two identical walking exercise sessions on a treadmill. one session will occur until continuous calcium infusion and the other will be under continuous saline infusion. c-telopeptide, parathyroid hormone, total calcium, and serum ionized calcium will be monitored to distinguish differences in bone activity under the two conditions.

Eligibility criteria:
inclusion criteria: * healthy adults aged 60-80 y * currently taking a bisphosphonate medication exclusion criteria: * use of medications (other than bisphosphonates) in the past 6 months known to affect bone metabolism (e.g., thiazide diuretics, oral glucocorticoids) * bone mineral density (bmd) t score \< -3.0 at the total hip or lumbar spine * known disease or condition associated with intestinal malabsorption * moderate or severe renal impairment defined as an estimated glomerular filtration rate of \<60 ml/min/1.73m2 based on the modified diet in renal disease (mdrd) equation * chronic hepatobiliary disease, defined as liver function tests (ast, alt) \>1.5 times the upper limit of normal; if such values are obtained on initial screening and thought to be transient in nature, repeated testing will be allowed * thyroid dysfunction, defined as an ultrasensitive tsh \ 5.0 mu/l; volunteers with abnormal tsh values will be re-considered for participation in the study after follow-up evaluation by the pcp with initiation or adjustment of thyroid hormone replacement * serum calcium \ 10.3 mg/dl serum 25(oh)d \ 20 ng/ml after vitamin d supplementation * uncontrolled hypertension defined as resting systolic bp \>150 mmhg or diastolic bp\>90 mmhg; participants who do not meet these criteria at first screening will be re-evaluated, including after follow-up evaluation by the pcp with initiation or adjustment of anti-hypertensive medications * history of type 1 or type 2 diabetes * cardiovascular disease; subjective or objective indicators of ischemic heart disease (e.g., angina, st segment depression) or serious arrhythmias at rest or during the graded exercise test (gxt) without follow-up evaluation will be cause for exclusion; follow-up evaluation must include diagnostic testing (e.g., stress echocardiogram or thallium stress test) with interpretation by a cardiologist * diagnosis or history of asthma
hybrid telehealth in pediatric physical therapy

Conditions: Pediatric Disorder; Disability, Developmental

Summary: the purposes of this study are to compare the impact of a hybrid of telehealth and in-person physical therapy services to in-person services alone on the in-home functional skills of children with moderate to severe disability. this is a mixed methods study.

the purposes of this study are to compare the impact of a hybrid of telehealth and in-person physical therapy services to in-person services alone on the in-home functional skills of children with moderate to severe disability. research questions include: is a hybrid of telehealth and in-person physical therapy service better than in-person services alone for improving in-home functional skills in children with moderate to severe disability? is there a difference in the satisfaction of caregivers and children with physical therapy services which consist of a hybrid of telehealth and in-person physical therapy services compared to in-person services alone? what is the experience of children and caregivers who receive a hybrid of telehealth and in-person physical therapy services during an episode of care?

Eligibility criteria:
inclusion criteria: * children 2-17 years old with moderate to significant disability. * families have access to minimum technology necessary to participate in a telehealth visit. ---the child's insurance covers telehealth visits. exclusion criteria: -caregiver does not speak english
attention training to modify error-related negativity and risk for anxiety in adolescence

Conditions: Anxiety

Summary: this is a multi-site study to examine error-related brain activity (i.e., the error-related negativity) and anxiety symptoms in 11 to 14 year-olds (n=600) at two time points separated by two years. the study examines the degree to which error-related negativity can predict anxiety prospectively over two years, and whether a computerized game that alters attention to threat can alter error-related negativity and trajectories of anxiety.

approximately 600 youths between the ages of 11 and 14 and their parents will be assessed. adolescents will be evaluated at baseline using event-related potentials, self-report, and interview-based measures. the error-related negativity will be evaluated immediately (it takes less than 5 minutes to process and score a single subjects' error-related negativity ), and adolescents with good error-related negativity data (\~90%, based on scorable error-related negativity data) will be randomly assigned to either an 8-week (i.e., 16 session) adaptive attention bias modification (n=180) or control condition (n=180) or a waitlist condition (n=180) group. each session lasts 20 minutes, and participants will be asked to complete two 20-minute sessions per week. participants will be assessed immediately at post, using the same measures from the baseline assessment. all participants will complete a 2-year follow-up lab visit using the same measures from the baseline assessment.

Eligibility criteria:
inclusion criteria: * children and parent must speak english well enough to complete the study assessments exclusion criteria: * current threat of harm to self or others, bipolar illness, psychosis, thought disorder, pervasive developmental disorder, mental retardation, neurological diseases that impair cognition, or significant head injuries (past 3 months).
pharmacists' knowledge and attitudes about adrs reporting and pharmacovigilance practice in egyptian hospitals

Conditions: Adverse Drug Reaction

Summary: the present study has assessed the knowledge, attitude and practice of adrs reporting among pharmacists, and the perceived factors that may influence reporting.

the practice and science of pharmacovigilance is described as the gathering, identification, monitoring, assessment, and prevention of adverse medication effects using pharmaceutical products. the term "pharmacovigilance" comes from the greek words pharmakon (drug) and vigilare (vigilance) (monitor or keep an eye on). pharmacovigilance (pv) is defined by the world health organization (who) as "the science and practices relating to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems". pv assesses the risk-benefit profile of medicines in order to improve patient safety. as a result, adverse drug reaction (adr) reporting is the bedrock of any pv system, and early detection and reporting of adrs to regional or national drug-regulatory bodies is important. adrs are defined by the world health organization as an unpleasant and unexpected response to a medicine that occurs at levels usually employed in man for the prevention, diagnosis, or therapy of disease, or for the alteration of physiological function". adverse drug reactions (adrs) are major public health issues that have been linked to longer hospital stays and higher therapeutic costs. according to recent systematic reviews and meta-analyses of observational research, the rate of hospital admissions linked to adrs is between 3-5 percent. a number of factors have been linked to hcps, particularly pharmacists, reporting adrs. several studies have indicated reasons for not reporting observed adrs, and pharmacists have been polled to determine the most important facilitators and barriers to spontaneous reporting. the seven deadly sins were coined by inman and later defined by lopez-gonzalez et al., into professional and personal traits, as well as knowledge and attitudes toward reporting. pharmacists from throughout the world have highlighted a number of barriers to reporting adrs, including a lack of time, the inability to correlate an adverse event (ae) to a specific medicine, and the absence of readily available reporting forms . it has also emphasized the necessity of educational measures to encourage adr reporting, such as awareness lectures and workshops. egypt joined the who international program for drug monitoring in 2001, but no concrete actions were done until 2009, when the egyptian pharmacovigilance center was established (epvc). receiving adr reports, detecting safety signals, sending frequent newsletters with pharmacovigilance (pv)-related updates, and conducting awareness training are only a few of epvc's responsibilities.

Eligibility criteria:
inclusion criteria: - pharmacist graduates exclusion criteria: undergrauate pharmacist -
assessment of arterial dynamic elastance as a function variable of arterial load

Conditions: Hypovolemia

Summary: the goal of the study is to determine eadyn as a functional measure of arterial load, in conjunction with other actual afterload indices, derived from both invasive arterial pressure tracing and non-invasive signals, such as arterial saturation, non-invasive cardiac output obtained by bio-reactance, and non-invasive stroke volume. a secondary aim is the correlation of the different non-invasive signals with the invasive arterial pressure tracing characteristics.

fifteen patients, who provide written informed consent, will be included. all of them are scheduled for a major surgical intervention, in whom standard haemodynamic monitoring includes arterial pressure monitoring. non-invasive wired patches, connected to a cheetah cardiac output monitor, will be installed, as well as traditional haemodynamic monitoring (ecg, sao2, non-invasive blood pressure). a computer link between a philips monitor (mp50 or mp70) is made, to obtain selected curves in a digital format for post-intervention processing. after awake insertion of an arterial catheter in the radial or brachial artery and induction of anaesthesia, patient becomes intubated and mechanically ventilated. before surgery, following data will be registered for 5 min.: ecg, invasive arterial pressure tracing, cardiac output (cheetah monitor), sao2 tracing, arterial pressure tracing and pulse pressure and stroke volume variation (nexfin). when svv \> 15%, the operation table will be put in passive leg raising (plr) to optimize the filling status of the patient (test of preload dependency). when positive haemodynamic reaction is present, the patients will obtain a rapid infusion bolus of 250 ml of crystalloids.

Eligibility criteria:
inclusion criteria: * all patients scheduled for a major surgical intervention, in whom standard haemodynamic monitoring includes arterial pressure monitoring. exclusion criteria: * minor surgery and absence of arterial pressure monitoring

Keywords: elastance fluid responsiveness
efficiency and safety of nasal positive airway pressure systems during endoscopy

Conditions: Hypercapnia; Hypoxia

Summary: goal of our study is to investigate whether the implication of nasal positive airway pressure (npap) system on patients with high periprocedural risk could significantly lower the incidence of severe hypoxia and hypercarbia. furthermore, we have set up goals to assess key components and factors, which lead to development of hypercarbia during endoscopy.

sedation of high-risk patients resemble a relevant issue in interventional endoscopy. this especially because standard oximetric monitoring displays only hypoxia and not the preceding hypercapnia. therefore, the question arises whether the implication of a nasal positive airway pressure (npap) system can decrease the rate of sedation associated events. the null hypothesis: the incidence of hypoxia in interventional group, using nasal positive airway pressure system, in comparison to control group with conventional oxygen supplementation canula is not significant. alternative hypothesis: the incidence of hypoxia in interventional group, using nasal positive airway pressure system is significantly lower, than in a control group with conventional oxygen supplementation canula

Eligibility criteria:
inclusion criteria: * asa iii (poorly controlled diabetes melitus (dm) or arterial hypertension (htn), chronic obstructive pulmonary disease (copd), morbid obesity (bmi≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, end stage renal disease (esrd), advanced liver disease ( acld) ; history (\>3 months) of myocardial infarction, coronary artery disease (cad) , transient ischemic attack (tia), or cad/stents) * asa iv (recent (\<3 months mi, cva, tia, or cad/stents, ongoing cardiac ischemia or severe valve dysfunction, severe reduction of ejection fraction, sepsis, ard or esrd not undergoing regularly scheduled dialysis * active malignancy (ecog performance \>2) exclusion criteria: * patients with tracheotomy * pregnancy * intubation assisted endoscopy * procedure without sedation